Barrett's Esophagus Clinical Trial
Official title:
The Effect of Proton Pump Inhibitors on Transmucosal Esophageal Leak
In a related study, the investigators have found evidence that patients with Barrett's esophagus have a leak for oral sucrose to leave their upper gastrointestinal tract, enter the blood, and be filtered into urine. The amount of sucrose appearing in an overnight urine sample can be used to indicate the presence of Barrett's esophagus and/or esophagitis in a patient reporting with reflux (GERD) symptoms. The leak is presumably in the Barrett's epithelium itself. This phenomenon will be used to test if a standard 8 week therapy of Nexium in a first-time-presenting GERD patient can reduce the leak as a means of assessing the efficacy of the drug in that patient. The investigators predict that Nexium will reduce leak in esophagitis but not Barrett's patients.
In a related study, we have found evidence that patients with Barrett's esophagus have a leak
for oral sucrose to leave the lumen of their upper gastrointestinal tract, enter the blood,
and be filtered into urine. Normally the disaccharide sucrose cannot leave the lumen of the
gastrointestinal tract without being first hydrolyzed to glucose and fructose. Appearance of
the disaccharide in the bloodstream suggests a paracellular leak of some type in the upper
gastrointestinal tract. Once in the blood, sucrose is likewise not taken up or metabolized by
the kidney but simply filtered into the urine. The amount of sucrose appearing in an
overnight urine sample can be used to indicate the presence of Barrett's esophagus and/or
esophagitis in a patient reporting with reflux (GERD) symptoms. The leak is presumably in the
Barrett's epithelium itself. This phenomenon will be used to test if a standard 8 week
therapy of Nexium in a first-time-presenting GERD patient can reduce the leak as a means of
assessing the efficacy of the drug in that patient. We predict that Nexium will reduce leak
in esophagitis but not Barrett's patients.
In this study, patients over 18 years of age presenting with GERD symptoms to a primary care
physician, will be recruited after providing informed consent. Patients will perform a
sucrose leak test the evening after their recruitment by drinking a solution of 100 gms of
sucrose in 200 cc of water at bedtime, then collecting an overnight urine sample (8 hrs).
Within 5 days the patient will undergo an upper endoscopy exam. The patient will then begin
Nexium therapy (40 mg/day of Esomeprazole) for 8 weeks, taking the dose each morning before
breakfast. After 8 weeks the patient will undergo a second sucrose leak test as described
above. Urine sucrose will be determined by HPLC.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02864043 -
Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System
|
N/A | |
Recruiting |
NCT02018367 -
Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01572987 -
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
|
N/A | |
Terminated |
NCT01976351 -
Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus
|
N/A | |
Terminated |
NCT00526786 -
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
|
Phase 4 | |
Completed |
NCT01401699 -
Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
|
N/A | |
Completed |
NCT02106910 -
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy
|
N/A | |
Suspended |
NCT01580631 -
Narrow Band Imaging Project on Barrett's Esophagus
|
||
Completed |
NCT01439633 -
Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
|
N/A | |
Completed |
NCT02879721 -
Expression and Function of the Renin-Angiotensin System in the Esophagus
|
Phase 0 | |
Completed |
NCT01281618 -
Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus
|
N/A | |
Completed |
NCT01439594 -
Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
|
N/A | |
Completed |
NCT00844077 -
Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus
|
N/A | |
Completed |
NCT00586872 -
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
|
||
Completed |
NCT00588575 -
Ramanspectroscopy in Barrett's Esophagus
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Completed |
NCT03813381 -
CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).
|
N/A | |
Completed |
NCT02579460 -
Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition
|
N/A | |
Completed |
NCT01961778 -
Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT02033070 -
Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System
|
N/A |